Table 2.
Biochemical characteristics of the study population
| Nondiabetic Patients | Diabetic Patients | P Value | |
|---|---|---|---|
| Metabolic biochemical parameters | |||
| Fasting glucose, mg/dl | 96.86 ± 1.78 | 129.0 ± 4.85 | <0.0001*** |
| Fasting insulin, mU/l | 5.40 ± 0.66 | 10.95 ± 2.28 | 0.417 |
| Fasting C-peptide, ng/ml | 2.14 ± 0.09 | 2.11 ± 0.12 | 0.831 |
| HOMA-IR, units | 1.32 ± 0.16 | 3.94 ± 0.88 | 0.013* |
| HOMA-β, units | 64.44 ± 7.97 | 65.32 ± 13.45 | 0.017* |
| QUICKI, units | 0.40 ± 0.01 | 0.38 ± 0.01 | 0.063 |
| Kidney biochemical parameters, mg/dl | |||
| Urea | 21.83 ± 0.88 | 25.58 ± 1.61 | 0.145 |
| Creatinine | 1.07 ± 0.13 | 1.10 ± 0.06 | 0.052 |
| Liver biochemical parameters, U/l | |||
| GOT | 27.47 ± 1.29 | 24.47 ± 1.93 | 0.183 |
| GPT | 28.47 ± 2.42 | 26.33 ± 3.03 | 0.585 |
| GGT | 37.90 ± 3.39 | 38.08 ± 6.29 | 0.334 |
| ALP | 67.36 ± 2.51 | 78.29 ± 4.18 | 0.054 |
| LDH | 212.7 ± 6.83 | 196.8 ± 11.60 | 0.017* |
| Non-CAD patients | |||
| INR, units | 1.40 ± 0.07 | 1.53 ± 0.159 | 0.402 |
| CK, U/l | 134.2 ± 19.90 | 110.2 ± 20.39 | 0.464 |
| CAD patients | |||
| INR, units | 1.26 ± 0.09 | 1.21 ± 0.06 | 0.740 |
| CK, U/l | 113.0 ± 12.99 | 88.71 ± 15.30 | 0.230 |
Data are presented as means ± SE. HOMA-IR, homeostatic model assessment-insulin resistance index; HOMA-β, HOMA-β-cell function; QUICKI, quantitative insulin sensitivity check index; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; GGT, γ-glutamyl transferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; INR, international normalized ratio; CK, creatine kinase. For normally distributed data, a parametric t-test was performed, whereas a nonparametric Mann-Whitney test was applied for nonnormally distributed data. P <0.05 was considered significant.
*
P ≤ 0.05;
***
P ≤ 0.001.